secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001213900-25-023762
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics FY2024 net loss $10.7M; cash $10.0M; Abbott collaboration for Phase 3 tecarfarin trial
--------------------------------------------------------------------------------

- Net loss of $10.7M for FY2024 (vs $8.4M in 2023); G&A expenses nearly doubled to $6.8M.
- Cash and equivalents of $10.0M as of Dec 31, 2024, up from $8.4M year-end 2023; ~1.8M shares outstanding.
- Collaboration with Abbott (NYSE: ABT) to support pivotal Phase 3 TECH-LVAD trial of tecarfarin.
- FDA Type D meeting in Feb 2025 provided guidance for tecarfarin Phase 3 trial design; FDA requested full study synopsis.
- Appointed Dr. James J. Ferguson as CMO and Jeff Cole as COO; received ODD for tecarfarin in LVAD patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025023762/0001213900-25-023762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025023762/ea023436601-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-023762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer